Compare HLN & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | EW |
|---|---|---|
| Founded | 2022 | 1958 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 50.2B |
| IPO Year | N/A | 1999 |
| Metric | HLN | EW |
|---|---|---|
| Price | $9.70 | $78.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 21 |
| Target Price | N/A | ★ $96.21 |
| AVG Volume (30 Days) | ★ 7.9M | 4.0M |
| Earning Date | 02-26-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | $6.77 | $13.39 |
| Revenue Next Year | $4.42 | $9.78 |
| P/E Ratio | $49.05 | ★ $42.67 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $8.71 | $68.63 |
| 52 Week High | $11.42 | $87.89 |
| Indicator | HLN | EW |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 37.65 |
| Support Level | $9.60 | $77.60 |
| Resistance Level | $9.96 | $78.64 |
| Average True Range (ATR) | 0.13 | 1.96 |
| MACD | 0.01 | -0.36 |
| Stochastic Oscillator | 0.00 | 12.42 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.